INDICATION & USAGE
IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.
Important Safety Information
Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO. Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.
Vaccination with IXIARO may not protect all individuals. Individuals with a weakened immune system may have a diminished immune response to IXIARO. Fainting may occur when receiving any injection, including IXIARO. Tell your healthcare practitioner if you have a history of fainting from injections.
The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.
You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. You should ask your healthcare practitioner for medical advice about adverse events.
For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.
Thailand
Vietnam
Vietnam
Only a bite?
Ummm … you better read this.
Japanese encephalitis (JE) is caused by a mosquito-borne virus specific to Asia and the western Pacific. Although rare, when viral infection results in JE disease, the consequences can be life-altering or deadly.
HOw JE infection works
A mosquito bites a pig or waterfowl (wading birds) carrying the JE virus, and at some point after that, bites a human.
What happens next can vary. Some people won’t be impacted at all—they won’t experience any symptoms, and the infection will clear. They’ll never know they had it.
Some experience mild, flu-like symptoms, and they’ll think it’s just that. The flu. And then the infection will clear, and they’ll never know they just dodged a major bullet.
In rare cases, JE infection can cause brain swelling and stroke-like symptoms that can lead to permanent brain damage or death.
It’s unknown why some people clear the virus, while others suffer devastating consequences.
The cold, hard facts
Japanese Encephalitis is
NOT JUST IN JAPAN.
Don’t let the name fool you. The first case of the disease was discovered in Japan, hence its name. But today, Japanese encephalitis is local to more than 20 countries across Asia and the western Pacific. Depending on your itinerary and plans, the Centers for Disease Control and Prevention advises to get protected if you’re traveling to any of the following destinations.
Japanese Encephalitis is
NOT JUST IN JAPAN
Don’t let the name fool you. The first case of the disease was discovered in Japan, hence its name. But today, Japanese encephalitis is local to more than 20 countries across Asia and the western Pacific. Depending on your itinerary and plans, the Centers for Disease Control and Prevention advises to get protected if you’re traveling to any of the following destinations.
Australia
Cambodia
Laos
Papua New Guinea
Taiwan
Bandgladesh
China
Malaysia
Philippines
Thailand
Bhutan
India
Nepal
Singapore
Timor-Leste
Brunei
Indonesia
North Korea
South Korea
Vietnam
Burma
Japan
Pakistan
Sri Lanka
Most people infected with JE virus are asymptomatic or experience only mild symptoms.1
Up to 50% of JE survivors suffer from persistent neurological problems
such as paralysis, recurring seizures,
or the inability to speak.
Even with local vaccination programs there are approximately
68,000 cases each year
(and this is just what’s reported)
UP TO 30% WILL DIE AS A RESULT OF SEVERE INFECTION
Most people infected with JE virus are asymptomatic or experience only mild symptoms.1
Even with local vaccination programs there are approximately
68,000 cases each year
(and this is just what’s reported)
Approximately
30% of people die as a result of severe infection
Up to 50% of JE survivors suffer from persistent neurological problems
such as paralysis, recurring
seizures, or the inability
to speak.
Up to 50% of JE survivors suffer from persistent neurological problems
such as paralysis, recurring seizures, or the inability to speak.
COMPLICATIONS OF JE CAN INCLUDE
- Cognitive and behavioral disturbances
- Memory impairment
- Cranial nerve defects
- Sensory disturbances, including pain
- Seizures
- Neuromuscular dysfunction
- Neurochemical and hormonal disturbances
- Impairment of activities of daily living (ADLs)
Even if most infections are asymptomatic, you never know who will develop severe symptoms of JE. Why risk it?
Treatment can range from immediate life-support measures to long-term rehabilitation.
There is no cure
Treatment can range from immediate life-support measures to long-term rehabilitation.
There is no cure
Treatment can range from immediate life-support measures to long-term rehabilitation.
There is no cure
Even if most infections are asymptomatic, you never know who will develop severe symptoms of JE. Why risk it?
Reference
- World Health Organization. Fact sheets. Japanese encephalitis. Published May 2019. https://www.who.int/news-room/fact-sheets/detail/japanese-encephalitis. Accessed October 14, 2022.
Indication & Usage
IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.
Important Safety Information
Severe allergic reaction after a previous dose of IXIARO, other Japanese encephalitis vaccine, any or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO. Individuals with a history of severe allergic reaction to another Japanese Encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.
Vaccination with IXIARO may not protect all individuals. Individuals with a weakened immune system may have a diminished immune response to IXIARO. Fainting may occur when receiving any injection, including IXIARO. Tell your healthcare practitioner if you have a history of fainting from injections.
The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.
You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. You should ask your healthcare practitioner for medical advice about adverse events.
For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.
Valneva USA, Inc.
4550 Montgomery Ave.,
Suite 460
Bethesda, MD 20814 USA
Site is intended for travelers from the United States
US-IXI-2200027 | Copyright © 2022 Valneva USA, Inc. All Rights Reserved.
